NMTC (NeuroOne Medical Technologies) Beneish M-Score: 1.52 (As of Jun. 26, 2026)

What is NeuroOne Medical Technologies Beneish M-Score?

NeuroOne Medical Technologies NMTC -4.04% 43 Beneish M-Score is 1.52 as of Jun. 26, 2026. GuruFocus rates NMTC with a GF Score™ of 43/100 and a GF Value™ of $6.58 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 766 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 96.08% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 1.52 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for NeuroOne Medical Technologies's Beneish M-Score or its related term are showing as below:

NMTC' s Beneish M-Score Range Over the Past 10 Years
Min: -5.36 Med: -1.44 Max: 198.66
Current: 1.52

During the past 13 years, the highest Beneish M-Score of NeuroOne Medical Technologies was 198.66. The lowest was -5.36. And the median was -1.44.

NeuroOne Medical Technologies Beneish M-Score Related Terms

NeuroOne Medical Technologies Beneish M-Score Historical Data

* Premium members only.

The historical data trend for NeuroOne Medical Technologies's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroOne Medical Technologies Beneish M-Score Chart

NeuroOne Medical Technologies Annual Data

Trend

Dec16

Dec17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

Beneish M-Score

Get a 7-Day Free Trial

0.00

-3.89

5.20

-3.11

-0.45

NeuroOne Medical Technologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beneish M-Score	Get a 7-Day Free Trial															-5.36	-4.05	-0.45	-3.17	1.52

NMTC vs CTSO, CODX, PETV: Beneish M-Score Comparison

For the Medical Devices subindustry, NeuroOne Medical Technologies's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroOne Medical Technologies Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's Beneish M-Score falls into.

Save Embed

43GF Score

NeuroOne Medical Technologies Corp NMTC

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NeuroOne Medical Technologies Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of NeuroOne Medical Technologies for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 4.5073

0.528 * 0.9942

0.404 * 0.3441

0.892 * 1.688

0.115 * 0.7587

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.5538

4.679 * 0.045772

0.327 * 0.5123

1.52

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was $2.43 Mil.
Revenue was 2.391 + 2.893 + 2.741 + 1.696 = $9.72 Mil.
Gross Profit was 1.287 + 1.568 + 1.529 + 0.915 = $5.30 Mil.
Total Current Assets was $7.40 Mil.
Total Assets was $7.87 Mil.
Property, Plant and Equipment(Net PPE) was $0.43 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.26 Mil.
Selling, General, & Admin. Expense(SGA) was $7.21 Mil.
Total Current Liabilities was $1.69 Mil.
Long-Term Debt & Capital Lease Obligation was $0.09 Mil.
Net Income was -2.086 + -1.438 + -1.619 + -1.501 = $-6.64 Mil.
Non Operating Income was 0.015 + 0.269 + -0.248 + 0.395 = $0.43 Mil.
Cash Flow from Operations was -1.329 + -3.116 + -1.526 + -1.464 = $-7.44 Mil.

Total Receivables was $0.32 Mil.
Revenue was 1.387 + 3.274 + 0.272 + 0.826 = $5.76 Mil.
Gross Profit was 0.771 + 1.927 + 0.141 + 0.282 = $3.12 Mil.
Total Current Assets was $3.75 Mil.
Total Assets was $4.46 Mil.
Property, Plant and Equipment(Net PPE) was $0.65 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.26 Mil.
Selling, General, & Admin. Expense(SGA) was $7.71 Mil.
Total Current Liabilities was $1.76 Mil.
Long-Term Debt & Capital Lease Obligation was $0.21 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(2.427 / 9.721)	/	(0.319 / 5.759)
	=	0.249666	/	0.055392
	=	4.5073

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(3.121 / 5.759)	/	(5.299 / 9.721)
	=	0.541934	/	0.545109
	=	0.9942

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (7.404 + 0.427) / 7.865)	/	(1 - (3.754 + 0.647) / 4.457)
	=	0.004323	/	0.012565
	=	0.3441

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	9.721	/	5.759
	=	1.688

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.258 / (0.258 + 0.647))	/	(0.257 / (0.257 + 0.427))
	=	0.285083	/	0.375731
	=	0.7587

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(7.205 / 9.721)	/	(7.708 / 5.759)
	=	0.741179	/	1.338427
	=	0.5538

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.092 + 1.689) / 7.865)	/	((0.207 + 1.763) / 4.457)
	=	0.226446	/	0.442001
	=	0.5123

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-6.644 - 0.431	-	-7.435)	/	7.865
	=	0.045772

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

NeuroOne Medical Technologies has a M-score of 1.52 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 1.52 mean?

NeuroOne Medical Technologies (NMTC) has a Beneish M-Score of 1.52 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on NeuroOne Medical Technologies and its competitors. According to the industry distribution chart, NeuroOne Medical Technologies ranks #736 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 96.1%.

Is NeuroOne Medical Technologies' Beneish M-Score too high?

NeuroOne Medical Technologies' current Beneish M-Score is 1.52. Based on the distribution chart, NeuroOne Medical Technologies ranks #736 out of 766 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does NeuroOne Medical Technologies' Beneish M-Score compare to CTSO and CODX?

According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #736 out of 766 companies for Beneish M-Score. This places NeuroOne Medical Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Medical Devices & Instruments company?

A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current Beneish M-Score is 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NeuroOne Medical Technologies stock overvalued right now?

Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.58, compared to a current price of $3.25 — trading 50.6% below its estimated fair value. The current Beneish M-Score is 1.52. NeuroOne Medical Technologies' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Beneish M-Score is 1.52 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued. The current stock price of $3.25 is trading 50.6% below its estimated GF Value™ of $6.58. GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.

Key valuation signals for NMTC:

Beneish M-Score: 1.52
GF Value™: $6.58 vs. price of $3.25 (50.6% below fair value)
GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroOne Medical Technologies Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies CTSO CODX PETV RDGL MODD FOFA VNRX GTHP LFWD NSYS ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344

Website https://www.n1mtc.com

NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.

43GF Score

Get the complete analysis for NMTC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25

Price

$6.58

GF Value

View NMTC Analysis

See Beneish M-Score data for all stocks →